[Update] Contract research organization Quintiles returned to the public markets today, trading on the NYSE under the stock symbol Q. It raised $947 million after it was priced at $40. Although the ...

May 3 (Reuters) - Contract medical research provider Quintiles Transnational Holdings Inc agreed to merge with healthcare information company IMS Health Holdings Inc in a deal worth about $9 billion.

Dennis Gillings doesn’t give many interviews and today, the day his Quintiles successor was announced, he wasn’t available to talk either. I’ve had a few occasions to talk with Gillings and our most ...

Quintiles IMS Holdings (NYSE: Q), a service and information provider for the healthcare and life sciences industries, reported its third-quarter results on Thursday, Oct. 26. The company's results ...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Quintiles, the world’s largest biopharmaceutical services company, has been named to Fortune magazine’s “World’s Most Admired Companies” list for 2016, ...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Quintiles today announced that it has completed the acquisition of Encore Health Resources (Encore), a leader in the health-information analytics and ...

Quintiles ($Q) is back on the buyer's block for the first time since going public, agreeing to scoop up oncology-focused CRO Novella Clinical for an undisclosed sum ...

The current state of drug research studies traces back to a 1975 phone call between an executive at what was then the world's largest drug company and a 30-year-old Brit with longish hair and bushy ...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- Samsung Electronics Co., Ltd., the world’s largest electronics company, and its affiliated companies (“Samsung”) have entered into a strategic ...

RESEARCH TRIANGLE PARK, N.C.--To stay ahead of the diverse and evolving needs of its global customer base, Quintiles today announced it has signed an agreement to acquire Novella Clinical (Novella), a ...

The current state of drug research studies traces back to a 1975 phone call between an executive at what was then the world's largest drug company and a 30-year-old Brit with longish hair and bushy ...